Incorporated in 2003, Nanobiotix is headquartered in Paris, France and has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations. Nanobiotix has created three nanophysics-based technology platforms with multiple product applications: 1) nano-radioenhancers to help millions of patients receiving radiotherapy; 2) nanoprimers to overcome challenges with liver clearance and redefine the way drugs can be designed bioavailability; and 3) nanoparticles for disorders of the central and peripheral nervous system. For more information, visit www.nanobiotix.com

Nutcracker Therapeutics is an RNA therapeutics company that has combined advanced engineering with high-precision biosynthesis to deploy a platform that encompasses the design, delivery and manufacturing of RNA medicines. The company has initiated therapeutic programs with the support of clinical investigators at leading institutions. Its platform has the potential to reduce costs and cycle times with advantages in speed and capacity scaling over other manufacturing approaches. To learn more, please visit https://www.nutcrackerx.com/

Calla Lily Clinical Care is a medical device manufacturer developing the Callavid® vaginal drug delivery platform for a wide range of therapeutics for infertility/miscarriage, gynecological cancers and a healthy vaginal microbiome. To learn more, please visit https://www.callali.ly/

Biograil has developed a proprietary oral delivery technology called BIONDD™ (pronounced BEYOND). The technology fits into a standard size (00 or 0) capsule effectively delivering the active substance to the systemic circulation. Biograil team members were R&D responsible for developing the world’s first FDA approved injection molded tablet. To learn more, please visit: https://biograil.com/

Zephyrus Innovations (Zephyrus) is a privately-owned medical device company designing safety syringes and Closed System Transfer Devices (CSTDs), based in Vancouver, Canada. Zephyrus has developed the world’s 1st CSTD for Sub-Cutaneous and Intra-Muscular Injection to supplement an already FDA-cleared auto-retractable syringe.

DelAQUA Pharmaceuticals has developed a breakthrough drug formulation platform that makes it possible to (a) increase solubility of poorly soluble drugs up to 100,000-fold, making them more bioavailable and easier to deliver, (b) co-formulate 2 or more poorly soluble drugs in defined ratios in the same aqueous solution, improving therapeutic outcomes in vivo, and c) easily optimize the excipient chemistry and design to match the properties of the compounds of interest, maximizing drug loading up to 50% or more. Our mission is to hasten the successful formulation and development of therapies that address the unmet medical needs of patients in a broad spectrum of diseases.We are looking for additional partnering, licensing and development opportunities for our own development projects and yours. For more information, visit https://www.delaquapharma.com/

Safer Solutions for a more Sustainable World. To learn more, please visit https://www.gaylordchemical.com/

MyResearchLink transfers data from EHR systems directly to patients and research systems in almost real-time, removing the burden of manual data entry into EDC systems. We develop cutting edge technology for data interoperability across clinical systems, patient-controlled health data systems, and research systems. This improved data flow eases the burdens of clinicians while giving them more complete data, transmits important data from EHR systems and from patients to researchers in a more timely and accurate manner, and gives a voice to patients with more personalized engagement - which improves their healthcare experience. For more information, go to https://MyResearchLink.com

SDC delivers top-tier clinical trial services to pharmaceutical, biologic, and medical device/diagnostic companies since 2005. Our relationship-based service model begins with our strategic level consultants partnering with our clients to optimize their clinical development program. This approach, paired with our expert data services (biostatistics, data management/EDC, and IRT/IWRS) and network of alliance partnerships, allows us to provide flexible service solutions to advance clients programs from first-in-human through post-approval trials.

We deploy a variety of industry leading software solutions to meet study needs such as Safety, IRT, eSource, eConsent, EDC and ePRO, all plugged into SDC DataHub enabling superior analytics through SDC Insights, our system agnostic reporting backbone.

With a proven track record, SDC will help to ensure the successful execution of your clinical program. For more information, go to https://www.sdcclinical.com/

At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy sequence data in studies around the globe. Our microarrays also provide accurate, high-throughput genotyping for a range of applications. The innovative products that we provide are facilitating breakthroughs in many scientific areas, including oncology, reproductive health, genetic disease, precision medicine, agriculture, microbiology, and beyond. The progress we see being made in genomics inspires us to push the boundaries of what is possible so we can create the next generation of genomics solutions. For more information, go to https://www.illumina.com/

RNhale is revolutionizing the pharmaceutical landscape by developing a unique platform technology for formulating RNA-loaded lipid nanoparticles (LNPs) as an inhalable dry powder. This disruptive approach synergizes technological and pharmaceutical strategies to create a novel therapeutic formulation with significant advantages over common LNP-RNA delivery methods. The target is pulmonary diseases with vast addressable markets and undeniable medical needs. For more information, please visit https://www.rnhale.com